Program
Please note that this meeting will take place as an in-person event in Tampa and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the REGISTRATION page for details.
All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program is subject to change.
[R] – Remote Presentation
Monday, March 14, 2022
Tuesday, March 15, 2022
Plenary Session 1: Longitudinal Dissection of Resistance Evolution
Plenary Session 2: Clonal Evolution, Part I
Plenary Session 3: Generation of Genomic and Epigenomic Diversity
Wednesday, March 16, 2022
Plenary Session 4: Microenvironmental Selection
Plenary Session 5: Mechanisms and Dynamics of Resistance Emergence, Part I
AACR Cancer Evolution Working Group Session
Plenary Session 5: Mechanisms and Dynamics of Resistance Emergence, Part II
Plenary Session 5: Mechanisms and Dynamics of Resistance Emergence, Part II (continued)
Thursday, March 17, 2022
Plenary Session 6: Evolutionary Guided (Adaptive) Therapy to Prevent Emergence of Resistance
Plenary Session 7: Clonal Evolution, Part II
MONDAY, March 14, 2022
Welcome and Keynote Lectures
SESSION CHAIR: ANDRIY MARUSYK, H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, TAMPA, FLORIDA
5:30-7:05 p.m.
Welcome from Cochairs
Robert J. Gillies, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
Keynote Speakers
Title to be announced
Robert A. Gatenby, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
Title to be announced
Charles Swanton, The Francis Crick Institute and UCL Cancer Institute, London, United Kingdom
Opening Reception
7:05-9 p.m.
TUESDAY, March 15, 2022
Breakfast
7-8 a.m.
Plenary Session 1: Longitudinal Dissection of Resistance Evolution
SESSION CHAIR: MARCO GERLINGER, THE INSTITUTE OF CANCER RESEARCH, LONDON, UNITED KINGDOM
8-10:15 a.m.
Darwinian and non-Darwinian evolution of cancer drug resistance
Marco Gerlinger
Tracking population heterogeneity and chemoresistance with functionalized cell barcodes
Amy Brock, The University of Texas at Austin, Austin, Texas
Title to be announced
Trever G. Bivona, University of California San Francisco, San Francisco, California
Short talks from proffered abstracts
Break
10:15-10:45 a.m.
Panel Discussion: Genetic, epigenetic and functional heterogeneity in cancer: which one(s) can we call evolution?
MODERATOR: ROBERT J. GILLIES, H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, TAMPA, FLORIDA
10:45-11:45 a.m.
Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts
Robert A. Gatenby, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
Charles Swanton, The Francis Crick Institute and UCL Cancer Institute, London, United Kingdom
Additional Panelists to be Announced
Lunch on own
11:45 a.m.-2 p.m.
Plenary Session 2: Clonal Evolution, Part I
Session Chair: Iñigo Martincorena, Wellcome Sanger Institute, Hinxton, United Kingdom
2-3:45 p.m.
Title to be announced
Iñigo Martincorena
Outcompeting cancer
Louis M. Vermeulen, Academic Medical Center, Amsterdam, The Netherlands
Mapping malignant differentiation topographies with single cell multi-omics
Daniel A. Landau, Weill Cornell Medicine, New York, New York
Short talks from proffered abstracts
Break
3:45-4:15 p.m.
Plenary Session 3: Generation of Genomic and Epigenomic Diversity
SESSION CHAIR: RONG LI, JOHNS HOPKINS UNIVERSITY, BALTIMORE, MARYLAND
4:15-6:15 p.m.
Title to be announced [R]
Andrew P. Feinberg, Johns Hopkins University, Baltimore, MD
Models of mutagenesis and carcinogenesis by human APOBEC3 enzymes
Reuben S. Harris, University of Minnesota, Minneapolis, Minnesota
Title to be announced
Susan M. Rosenberg, Baylor College of Medicine, Houston, Texas
Short talks from proffered abstracts
POSTER SESSION A / RECEPTION
6:30-8 p.m.
WEDNESDAY, March 16, 2022
Breakfast
7-8 a.m.
Plenary Session 4: Microenvironmental Selection
Session Chair: Carlo C. Maley, Arizona State University, Tempe, Arizona
8-10 a.m.
Aging, tissue ecology, and the evolution of cancer within us
James V. DeGregori, University of Colorado, Aurora, Colorado
Genetic heterogeneity and tumor microenvironment in glioblastoma
Michalina Janiszewska, The Scripps Research Institute, Jupiter, Florida
Insights from comparative oncology
Carlo C. Maley
Short talks from proffered abstracts
Break
10-10:30 a.m.
Plenary Session 5: Mechanisms and Dynamics of Resistance Emergence, Part I
SESSION CHAIR: ANDRIY MARUSYK, H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, TAMPA, FLORIDA
10:30 a.m.-12:30 p.m.
Title to be announced
Renee Brady, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
Title to be announced
Catherine Wu, Dana-Farber Cancer Institute, Boston, Massachusetts
Resistance to targeted therapies as a gradual, multifactorial adaptation to inhibitor-specific selective pressures
Andriy Marusyk
Short talks from proffered abstracts
Additional speaker to be announced
AACR Cancer Evolution Working Group Session (Lunch Provided)
12:30-2 p.m.
Plenary Session 5: Mechanisms and Dynamics of Resistance Emergence, Part II
SESSION CHAIR: IVANA BOZIC, UNIVERSITY OF WASHINGTON, SEATTLE, WASHINGTON
2-5 p.m.
The polyaneuploid cancer cell state as a mediator of therapeutic resistance
Kenneth J. Pienta, Johns Hopkins School of Medicine, Baltimore, Maryland
Single-cell analysis of drug resistance, cellular memory, and plasticity in cancer
Sydney Shaffer, University of Pennsylvania, Philadelphia, Pennsylvania
Short talk from proffered abstracts
Break
3:15-3:30 p.m.
Plenary Session 5: Mechanisms and Dynamics of Resistance Emergence, Part II (continued)
3:30-5 p.m.
Title to be announced
Jacob G. Scott, Cleveland Clinic, Cleveland, Ohio
Evolutionary dynamics of resistance to cancer therapy
Ivana Bozic
Short talks from proffered abstracts
Poster Session B / Reception
5-7 p.m.
EVENING OFF / Dinner on Own
7 p.m.
THURSDAY, March 17, 2021
Breakfast
7-8 a.m.
Plenary Session 6: Evolutionary Guided (Adaptive) Therapy to Prevent Emergence of Resistance
SESSION CHAIR: ROBERT J. GILLIES, H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, TAMPA, FLORIDA
8-9:45 a.m.
Title to be announced
Rong Li, Johns Hopkins University, Baltimore, Maryland
Title to be announced
Alberto Bardelli, Candiolo Cancer Institute IRCCS, University of Turin, Italy
Selection for a glycolytic phenotype
Mehdi Damaghi, Stony Brook University, Stony Brook, New York
Short talk from proffered abstracts
Break
9:45-10:15 a.m.
Plenary Session 7: Clonal Evolution, Part II
SESSION CHAIR: CHRISTINA CURTIS, STANFORD UNIVERSITY, STANFORD, CALIFORNIA
10:15 a.m.-12:15 p.m.
The role of the epigenome and phenotypic plasticity in colorectal cancer evolution
Trevor Graham, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Decoding responses to chemotherapy in triple-negative breast cancer with single cell genomics
Nicholas E. Navin, The University of Texas MD Anderson Cancer Center, Houston, Texas
Quantifying clonal evolution through treatment and metastasis
Christina Curtis
Short talks from proffered abstracts
Closing Remarks
12:15 p.m.
James V. DeGregori, University of Colorado, Aurora, Colorado